Enhertu (trastuzumab deruxtecan), a targeted therapy for HER2-positive cancers, has shown promise in treating solid tumors, including nonsmall cell lung cancer (NSCLC) with brain metastases. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.